News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Amgen is reviewing data from chronic kidney disease (CKD) patients to assess what impact switching to a 'biosimilar' version of its blood cell booster Aranesp (Darbepoetin Alfa) has had on their disease.
editor's blog
Ramesses II didn't need Enbrel, Remicade, Humira or any other TNFα blocker according to a study that rejects the idea the pharaoh was plagued, all puns intended, by ankylosing spondylitis.
Correction
Generic drugmakers want biotherapeutic products to have general recommendations in the European Pharmacopoeia rather than individual monographs.
Biopharmas struggle to comply with GMP requirements for personalised meds and the outstanding questions mean some are reluctant to invest according to German firm immatics.